Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 3/20 | 0.52 |
| ▸ | BRD4 | O60885 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.52 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.52 |
| ▸ | NQO2 | P16083 | 3/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.40 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19751556 | 0.78 | MEN1 (0.38) | BRPF1BRD4CA12CA9KAT2B | |
| SCHEMBL28164543 | 0.78 | MEN1 (0.38) | BRPF1BRD4CA12CA9KAT2B | |
| SCHEMBL3107572 | 0.78 | MAPT (0.50) | BRPF1BRD4CA12CA9KAT2B | |
| SCHEMBL9367162 | 0.78 | CA12 (0.50) | BRPF1BRD4CA12CA9KAT2B | |
| SCHEMBL11274030 | 0.78 | BRPF1 (0.50) | BRPF1BRD4CA12CA9KAT2B | |
| SCHEMBL23346692 | 0.78 | BRPF1 (0.50) | BRPF1BRD4CA12CA9KAT2B | |
| SCHEMBL11286560 | 0.78 | BRPF1 (0.50) | BRPF1BRD4CA12CA9KAT2B | |
| SCHEMBL98218 | 0.77 | CYP19A1 (0.54) | BRPF1BRD4CA12CA9KAT2B | |
| SCHEMBL17505199 | 0.77 | CCNB2 (0.40) | BRPF1BRD4CA12CA9KAT2B | |
| SCHEMBL26555552 | 0.76 | BRPF1 (0.57) | BRPF1BRD4CA12CA9KAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20220127281-A1 | HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS | ASTRAZENECA UK LIMITED (GB) | 2022-04-28 | — | — | US | disclosed |
| US-20200109153-A1 | HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS | ASTRAZENECA AB (SE) | 2020-04-09 | — | — | US | disclosed |
| EP-1812426-B1 | ARYL SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS EHF (IS) | 2011-06-08 | — | — | EP | disclosed |
| EP-1812388-B1 | SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS EHF (IS) | 2011-02-23 | — | — | EP | disclosed |
| US-7714017-B2 | for prostaglandin-mediated disorders; (E)-3-[1-(2,4-Dichloro-benzyl)-3,3-bis-hydroxymethyl-2-oxo-2,3-dihydro-1H-indol-7-yl]-acrylic acid | DECODE GENETICS, EHF (IS) | 2010-05-11 | — | — | US | disclosed |
| US-7714017-B2 | for prostaglandin-mediated disorders; (E)-3-[1-(2,4-Dichloro-benzyl)-3,3-bis-hydroxymethyl-2-oxo-2,3-dihydro-1H-indol-7-yl]-acrylic acid | DECODE GENETICS, EHF (IS) | 2010-05-11 | — | — | US | disclosed |
| US-20090291948-A1 | SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS EHF (IS) | 2009-11-26 | — | — | US | disclosed |
| US-20090291948-A1 | SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS EHF (IS) | 2009-11-26 | — | — | US | disclosed |
| US-7598397-B2 | Sulfonamide peri-substituted bicyclics for occlusive artery disease | DECODE GENETICS EHF (IS) | 2009-10-06 | — | — | US | disclosed |
| EP-0623614-B1 | 4-Aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors | ZENECA LTD (GB) | 1998-02-25 | — | — | EP | disclosed |
| US-5512594-A | ADMINISTERING TO TREAT A MEDICAL CONDITION MEDIATED BY ONE OR MORE LEUKOTRIENES | ZENECA LIMITED (GB) | 1996-04-30 | — | — | US | disclosed |
| US-5478842-A | Antiinflammatory agents, antiallergens, drugs for treatment of diseases mediated by leukotrienes | ZENECA LIMITED (GB) | 1995-12-26 | — | — | US | disclosed |
| WO-1994025453-A1 | 4-ARYL-4-HYDROXY-TETRAHYDROPYRANS AND 3-ARYL-3-HYDROXY-TETRAHYDROFURANS AS 5-LIPOXYGENASE INHIBITORS | ZENECA LIMITED (GB) | 1994-11-10 | — | — | WO | disclosed |
| EP-0623614-A1 | 4-Aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors | ZENECA LIMITED (GB) | 1994-11-09 | — | — | EP | disclosed |
| EP-0420511-B1 | Heterocyclic derivatives | ICI PLC (GB) | 1994-08-17 | — | — | EP | disclosed |
| US-5302594-A | Antiinflammatory agents; antiallergenic agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-04-12 | — | — | US | disclosed |
| US-5221677-A | For treating diseases mediated by leukotrienes | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-06-22 | — | — | US | disclosed |
| EP-0420511-A2 | Heterocyclic derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-04-03 | — | — | EP | disclosed |
| US-4349554-A | Method of using carbostyril derivatives as plant fungicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1982-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200109153-A1 | HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS | KRAS, NRAS, HRAS | BRPF1 1127/4885BRD4 2178/4885CA12 4783/4885 |
| US-20220127281-A1 | HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS | KRAS, NRAS, HRAS | BRPF1 1099/4885BRD4 2289/4885CA12 4752/4885 |
| US-20090291948-A1 | SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | PTGIS, PTGIR, PTGS2 | BRPF1 1209/4885BRD4 465/4885CA12 1744/4885 |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | BRPF1 2834/4885BRD4 1469/4885CA12 3651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.